Literature DB >> 22118536

Both sitagliptin analogue & pioglitazone preserve the beta-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice.

Jin-A Yeom1, Eun Sook Kim, Heon-Seok Park, Dong-Sik Ham, Chenglin Sun, Ji-Won Kim, Jae-Hyoung Cho, Kun-Ho Yoon.   

Abstract

In this study, the effects of sitagliptin analogue (SITA) or pioglitazone (PIO) treatment on glucose homeostasis and Β-cell dynamics in animal models of type 2 diabetes--Akita and db/db mice were evaluated. After 4-6 weeks of treatment, both SITA and PIO were shown to lower non-fasting glucose levels and reduced glycemic excursion in the intraperitoneal glucose tolerance test. In addition, both drugs preserved normal islet structure and the proportion of Β-cells in the islets. Compared to the controls, SITA treatment induced a higher Β-cell proliferation rate in Akita mice and a lower rate of apoptosis in db/db mice, whereas PIO treatment induced a lower rate of apoptosis in db/db mice and reduced proliferation rates in Akita mice. In conclusion, both SITA and PIO appear to exert some beneficial effects on the islet structure in addition to glycemic control via different mechanisms that involve Β-cell dynamics in Akita and db/db mice. [BMB reports 2011; 44(11): 713-718].

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22118536     DOI: 10.5483/BMBRep.2011.44.11.713

Source DB:  PubMed          Journal:  BMB Rep        ISSN: 1976-6696            Impact factor:   4.778


  7 in total

1.  Therapeutic effects of an aspalathin-rich green rooibos extract, pioglitazone and atorvastatin combination therapy in diabetic db/db mice.

Authors:  Oelfah Patel; Christo J F Muller; Elizabeth Joubert; Bernd Rosenkranz; Johan Louw; Charles Awortwe
Journal:  PLoS One       Date:  2021-05-13       Impact factor: 3.240

2.  Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties.

Authors:  Flávio Reis; Edite Teixeira de Lemos; Cristina Mega; Helena Vala; Paulo Rodrigues-Santos; Jorge Oliveira; Frederico Teixeira; Rosa Fernandes
Journal:  Diabetol Metab Syndr       Date:  2014-03-20       Impact factor: 3.320

Review 3.  Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes.

Authors:  Cristina Mega; Edite Teixeira-de-Lemos; Rosa Fernandes; Flávio Reis
Journal:  J Diabetes Res       Date:  2017-08-27       Impact factor: 4.011

4.  Implanted islet mass influences the effects of dipeptidyl peptidase-IV inhibitor LAF237 on transplantation outcomes in diabetic mice.

Authors:  Jyuhn-Huarng Juang; Chen-Yi Chen; Chen-Wei Kao; Yu-Wen Huang; Tai-Yu Chiu; Chiung-Tong Chen
Journal:  Biomed J       Date:  2020-10-10       Impact factor: 7.892

Review 5.  Choice of therapy in patients with type 2 diabetes inadequately controlled with metformin and a sulphonylurea: a systematic review and mixed-treatment comparison meta-analysis.

Authors:  Brendan McIntosh; Chris Cameron; Sumeet R Singh; Changhua Yu; Lisa Dolovich; Robyn Houlden
Journal:  Open Med       Date:  2012-06-04

6.  Effects of Dipeptidyl Peptidase-4 Inhibition with MK-0431 on Syngeneic Mouse Islet Transplantation.

Authors:  Jyuhn-Huarng Juang; Chien-Hung Kuo; Ying-Hsiu Liu; Han-Ying Chang; Chiung-Tong Chen
Journal:  Int J Endocrinol       Date:  2014-08-04       Impact factor: 3.257

7.  Novel AGLP-1 albumin fusion protein as a long-lasting agent for type 2 diabetes.

Authors:  Yong-Mo Kim; Sang Mee Lee; Hye-Shin Chung
Journal:  BMB Rep       Date:  2013-12       Impact factor: 4.778

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.